Poster Session C - Monday Afternoon
Category: Functional Bowel Disease
Eamonn M. Quigley, MD, MACG
Houston Methodist Hospital
Houston, TX
|
| VC (Vibrant) Mean change from baseline ITT [95% CI] | Placebo Mean change from baseline ITT [95% CI] | P-value (χ2 test) |
Entire Study Population (ITT population from Phase III study)
VC n=163 Placebo n=149 | CSBM1 | 39.26% [32.10%;46.93%] | 22.15% [16.23%;29.47%] | 0.0011 |
CSBM2 | 22.70% [16.94%;29.72%] | 11.41% [7.25%;17.51%] | 0.0085 | |
ITT < 80% compliance
VC n=117 Placebo n=117 | CSBM1 | 26.09% [15.601%;40.26%] | 6.25% [1.73%;20.15%] | 0.0247 |
CSBM2 | 13.40% [6.12%;25.67%] | 3.13% [0.55%;15.74%] | 0.229) | |
ITT >=80% compliance
VC n=46 Placebo n=32 | CSBM1 | 44.44% [35.76%;53.48%] | 26.50% [19.34%;35.15%] | 0.0041 |
CSBM2 | 26.50% [19.34%;35.15%] | 13.68% [8.60%;21.06%]
| 0.0144 |